When should insulin therapy be started in diabetes, and what is the recommended initial regimen and titration strategy?

Insulin Therapy in Diabetes: Initiation, Regimen, and Titration

When to Start Insulin

Insulin should be initiated immediately as first-line injectable therapy when A1C is >10% (>86 mmol/mol) or blood glucose is ≥300 mg/dL (≥16.7 mmol/L), when symptoms of hyperglycemia are present, or when type 1 diabetes is a diagnostic possibility. 1

For patients not meeting these criteria, insulin is indicated when glycemic targets are not achieved despite lifestyle modifications and oral antidiabetic agents. 1, 2

Initial Insulin Regimen

Basal Insulin as First-Line

Start with basal insulin alone as the most convenient initial insulin regimen, which can be added to metformin and other agents. 1

Initiation dosing:

• 10 units per day OR 0.1-0.2 units/kg/day 1
• This conservative starting dose applies to basal analogs or bedtime NPH insulin 1

Choice of basal insulin:

• Long-acting basal analogs (glargine U-100, detemir, glargine U-300, or degludec) reduce nocturnal and level 2 hypoglycemia risk compared to NPH insulin 1
• Longer-acting analogs (glargine U-300, degludec) provide lower nocturnal hypoglycemia risk than glargine U-100 1
• Selection should be based on person-specific considerations including cost 1

Titration Strategy

Basal Insulin Titration

Use an evidence-based titration algorithm: increase by 2 units every 3 days to reach fasting plasma glucose (FPG) goal without hypoglycemia. 1

Alternative titration approaches include:

• Increase by 1 unit per day for NPH, detemir, and glargine U-100 3
• Increase by 2-4 units once or twice per week for NPH, detemir, glargine U-100/U-300, and degludec 3

Set individualized FPG goals (typically 80-130 mg/dL per standard glycemic targets) 1, 3

For hypoglycemia: Determine the cause; if no clear reason exists, lower the dose by 10-20% 1

Monitoring for Overbasalization

Assess insulin adequacy at every visit and watch for clinical signals of overbasalization: 1

• Basal dose exceeding 0.5 units/kg 1
• Elevated bedtime-to-morning glucose differential 1
• Elevated postprandial-to-preprandial glucose differential 1
• Hypoglycemia (aware or unaware) 1
• High glucose variability 1

Intensification When A1C Remains Above Goal

Before Adding Prandial Insulin

If A1C remains above goal and the patient is not already on a GLP-1 RA or dual GIP/GLP-1 RA, add these agents in combination with insulin (consider fixed-ratio products if available and appropriate) before advancing to prandial insulin. 1

This approach minimizes weight gain and hypoglycemia risk associated with prandial insulin. 1

Adding Prandial Insulin

If A1C remains above goal after optimizing basal insulin and considering GLP-1 RA therapy:

Initial prandial insulin approach:

• Start with one dose at the largest meal or meal with greatest postprandial glucose excursion 1
• Initiate at 4 units per day OR 10% of basal insulin dose 1
• Titrate by increasing 1-2 units or 10-15% based on individualized needs 1

If on bedtime NPH: Consider converting to twice-daily NPH plan with total dose = 80% of current bedtime NPH dose 1

Further intensification options if A1C remains elevated:

• Self-mixed/split insulin plan 1
• Twice-daily premixed insulin plan 1
• Full basal-bolus regimen (basal insulin plus prandial insulin with each meal) 1

For basal-bolus regimens: Give 2/3 of total daily dose before breakfast and 1/3 before dinner, with adjustments based on individualized needs 1

Critical Considerations

Continue metformin if possible as it reduces all-cause mortality and cardiovascular events in overweight patients with diabetes. 4

Prescribe glucagon for emergent hypoglycemia when initiating basal insulin. 1

Provide comprehensive education on blood glucose monitoring, nutrition, hypoglycemia avoidance and treatment, and self-titration techniques, as patient involvement in insulin management improves glycemic control. 1

Reassess and modify therapy regularly (every 3-6 months) to avoid therapeutic inertia. 1